DSM Biomedical and CID Partnership continues to advance device deliverability with the use of DSM ComfortCoat® Hydrophilic Coating
DSM Biomedical, a global leader in biomedical materials science, today announced the extension of its partnership with CID based on the use of DSM ComfortCoat® Hydrophilic coating technology on the Optima Jet Stent Delivery System and the Fluydo PTCA Balloon Catheter, both with CE mark and launched on the European market last month.
The DSM ComfortCoat Hydrophilic Coating was designed to enhance maneuverability of devices in minimally invasive procedures. This advanced lubricious hydrophilic coating on the distal part of the Optima Jet shaft facilitates the treatment of more complex anatomies. Additionally, the DSM ComfortCoat Hydrophilic Coating on the Fluydo PTCA Balloon contributes to further advance device deliverability in order to reach and cross the most difficult lesions.
“Following the successful launch of our bio-inducer surfaced stent Avantgarde last year and our continuous commitment to create new devices, we are excited to extend our partnership with DSM Biomedical in improving the quality of medical treatments. We value DSM Biomedical’s long-standing experience in biomaterials, and their commitment to support with innovative new materials that lead to positive medical outcomes”, said Mr. Franco Vallana, Chief Executive Officer, CID.
“Our partnership with CID is based on our shared vision of being dedicated to improving the quality of patient care and after-care through enabling innovation in medical solutions. We look forward to collaborating with them on future technologies”, said John Marugg, DSM Biomedical’s Business Director for ComfortCoat medical coatings.
CID (Carbostent & Implantable Devices) is dedicated to contributing to human welfare by improving the quality of patient care and after-care through the development of innovative, minimally invasive implantable devices,procedures and therapies. A strong background in the field of implantable cardiovascular devices and haemocompatible materials, expressed in a remarkable IP portfolio, and a management with an expertise gained in many years of research, development and clinical experience, allow CID to offer the investors a fair return and its customers the necessary tools to meet new challenges. For more information, visit www.cidvascular.com.